Cubist Systematic Strategies LLC Purchases Shares of 24,364 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Cubist Systematic Strategies LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 24,364 shares of the company’s stock, valued at approximately $44,000.

A number of other large investors have also recently bought and sold shares of the stock. Towerview LLC grew its position in Corvus Pharmaceuticals by 4.6% in the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after acquiring an additional 17,500 shares during the period. Marshall Wace LLP bought a new stake in Corvus Pharmaceuticals in the second quarter valued at $136,000. Vanguard Group Inc. grew its holdings in shares of Corvus Pharmaceuticals by 10.6% during the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock worth $2,658,000 after purchasing an additional 142,724 shares during the last quarter. Samlyn Capital LLC increased its stake in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at $10,855,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Stock Up 9.4 %

Shares of CRVS stock opened at $7.35 on Thursday. The stock has a 50-day moving average price of $4.88 and a 200 day moving average price of $3.00. The firm has a market cap of $459.75 million, a price-to-earnings ratio of -14.13 and a beta of 1.14. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.05 and a 12 month high of $7.41.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.05. During the same period last year, the business earned ($0.14) earnings per share. Sell-side analysts predict that Corvus Pharmaceuticals, Inc. will post -0.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CRVS. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 11th. LADENBURG THALM/SH SH raised their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.83.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.